1474 related articles for article (PubMed ID: 18249467)
61. A high percentage of skin melanoma cells expresses SPANX proteins.
Salemi M; Calogero AE; Vicari E; Migliore E; Zaccarello G; Cosentino A; Amore M; Tricoli D; Castiglione R; Bosco P; Rappazzo G
Am J Dermatopathol; 2009 Apr; 31(2):182-6. PubMed ID: 19318807
[TBL] [Abstract][Full Text] [Related]
62. [Focal melanocytic atypia in dysplastic nevus cell nevi. Results of a serial section study].
Sigg C; Pelloni F; Schnyder UW
Hautarzt; 1989 Nov; 40(11):701-7. PubMed ID: 2606669
[TBL] [Abstract][Full Text] [Related]
63. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
[TBL] [Abstract][Full Text] [Related]
64. Nevi, other than dysplastic and Spitz nevi.
Cochran AJ; Bailly C; Paul E; Dolbeau D
Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
[TBL] [Abstract][Full Text] [Related]
65. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi.
Friedman RJ; Rigel DS; Kopf AW; Lieblich L; Lew R; Harris MN; Roses DF; Gumport SL; Ragaz A; Waldo E; Levine J; Levenstein M; Koenig R; Bart RS; Trau H
Arch Dermatol; 1983 Jun; 119(6):455-62. PubMed ID: 6859885
[TBL] [Abstract][Full Text] [Related]
66. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
[TBL] [Abstract][Full Text] [Related]
67. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
Tellez CS; Davis DW; Prieto VG; Gershenwald JE; Johnson MM; McCarty MF; Bar-Eli M
J Invest Dermatol; 2007 Feb; 127(2):387-93. PubMed ID: 16946713
[TBL] [Abstract][Full Text] [Related]
68. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
Dai DL; Martinka M; Li G
J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
[TBL] [Abstract][Full Text] [Related]
69. Malignant melanoma, dysplastic melanocytic nevi, and Spitz tumors. Histologic classification and characteristics.
Barnhill RL
Clin Plast Surg; 2000 Jul; 27(3):331-60, viii. PubMed ID: 10941557
[TBL] [Abstract][Full Text] [Related]
70. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
71. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi.
Holt JB; Sangueza OP; Levine EA; Shen P; Bergman S; Geisinger KR; Creager AJ
Am J Clin Pathol; 2004 Jan; 121(1):58-63. PubMed ID: 14750241
[TBL] [Abstract][Full Text] [Related]
72. Dysplastic nevi in relation to superficial spreading melanoma.
Titus-Ernstoff L; Barnhill RL; Duray PH; Ernstoff MS; Kirkwood JM
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):99-101. PubMed ID: 8467253
[TBL] [Abstract][Full Text] [Related]
73. Loss of EphB6 expression in metastatic melanoma.
Hafner C; Bataille F; Meyer S; Becker B; Roesch A; Landthaler M; Vogt T
Int J Oncol; 2003 Dec; 23(6):1553-9. PubMed ID: 14612926
[TBL] [Abstract][Full Text] [Related]
74. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma.
Ding Y; Prieto VG; Zhang PS; Rosenthal S; Smith KJ; Skelton HG; Diwan AH
Cancer; 2006 Mar; 106(5):1123-9. PubMed ID: 16456815
[TBL] [Abstract][Full Text] [Related]
75. Human melanoma cells express functional receptors for thyroid-stimulating hormone.
Ellerhorst JA; Sendi-Naderi A; Johnson MK; Cooke CP; Dang SM; Diwan AH
Endocr Relat Cancer; 2006 Dec; 13(4):1269-77. PubMed ID: 17158770
[TBL] [Abstract][Full Text] [Related]
76. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
77. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
78. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
[TBL] [Abstract][Full Text] [Related]
79. Neuropeptide Y expression in cutaneous melanoma.
Gilaberte Y; Roca MJ; Garcia-Prats MD; Coscojuela C; Arbues MD; Vera-Alvarez JJ
J Am Acad Dermatol; 2012 Jun; 66(6):e201-8. PubMed ID: 21620518
[TBL] [Abstract][Full Text] [Related]
80. Adhesion molecule profile and malignancy of melanocytic lesions.
Moretti S; Martini L; Berti E; Pinzi C; Giannotti B
Melanoma Res; 1993 Aug; 3(4):235-9. PubMed ID: 8219755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
